The lack of prospective randomized clinical trials demonstrating that full-body skin examination (FBSE) reduces melanoma morbidity or mortality has prompted an "I" rating from the United States Preventive Services Task Force for population-based skin cancer screening. More data on these screening programs are needed.
M elanoma can be detected relatively quickly through a visual full-body skin examination (FBSE). 1 However, data supporting screening are limited. 2 The largest evaluation of melanoma screening by FBSE comes from a 1-year intervention in Schleswig-Holstein, Germany in which citizens 20 and older were invited to receive a 1-time skin cancer screening. 3, 4 Most screenings were performed by primary care physicians (PCPs), and melanoma mortality in the 5 years following was reduced by nearly 50%. 5 However, melanoma mortality rates drifted back to baseline despite the initiation of a national program targeting adults 35 years or older; a gap in screening in 2004 through 2008 may be partially responsible for this. To our knowledge, large-scale skin cancer screening in a health care system in the United States has not been reported. We describe an approach to melanoma screening that is novel in its scale and implementation as a quality initiative.
Methods
Data from the electronic health record (EHR) were used to track patients' screening status and melanomas diagnosed. Incidence and tumor thickness in the screened and unscreened population were compared. The screening initiative was approved by the University of Pittsburgh Medical Center (UPMC) as a quality-improvement project. Collection of outcome data and a waiver of patient written informed consent was approved by the University of Pittsburgh institutional review board. Patients were deemed screen eligible if they were 35 years or older and saw a UPMC-employed PCP for an office visit in 2014. Age 35 years was chosen based on data showing a low yield of melanoma diagnosis and a high rate of benign lesions excised in patients younger than 35 years in 1 screening program. 6 The EHR was modified to include FBSE as a preventive service recommendation for patients 35 years or older and to track if and when screening was performed. Participating PCPs documented that the patient was up to date with this screening if they performed the screening or if the patient reported receiving an FBSE in the past 12 months by another clinician. Patients were also considered screened if they had a skin cancer screening visit with a dermatologist documented in the EHR in 2014. The program was promoted by health care system leadership to physicians in town hall-style meetings and email communications and to patients in a health system newsletter. Training was offered to PCPs via INFORMED (INternet curriculum FOR Melanoma Early Detection), a previously validated web-based skin cancer identification training tool. Demographic data (age, sex, insurance status, and selfreported race and ethnicity [given the predominance of melanoma in non-Hispanic whites]) were collected from the EHR. Melanomas diagnosed in screen-eligible patients on or after the date the patient was first screened were identified using the UPMC cancer registry and text-based search of pathology reports. Patients diagnosed with melanoma in the 12 months prior to their screening visit (screened patients) or anytime in 2013 based on data from the UPMC cancer registry (unscreened patients), were excluded from analysis ( Figure) .
Descriptive statistics are used to report demographic characteristics. Comparisons between screened and unscreened patients were performed using the χ 2 test for discrete variables and Wilcoxon rank-sum test for continuous variables. Logistic regression was used to estimate the odds ratio (OR) of detecting a melanoma case vs noncases in the screened population compared with the unscreened population after adjustment for age, sex, race/ethnicity, and insurance status. Multinomial logistic regression was used to estimate the OR of detecting a melanoma in a specific category (in situ, invasive, or specific Breslow thickness) vs noncases in the screened population compared with the unscreened population after adjustment for age, sex, race/ethnicity, and insurance status.
Results
In 2014, 333 788 eligible individuals were seen in an office visit by a PCP. Twenty-nine screened patients were excluded because they had been diagnosed with melanoma in the year prior to their screen, and 24 patients were excluded from the unscreened group because they were diagnosed with melanoma in 2013; thus, 333 735 patients were included in analysis. Screening was declined by 3109 patients, and 53 196 screened patients were included in the screened cohort analysis ( In 2014, 50 patients in the screened population (21 men, 42%) and 104 patients in the unscreened population (51 men, 49%) were diagnosed with melanomas. Screened patients were more likely than unscreened patients to receive a melanoma diagnosis overall, and most of their melanomas were in situ or 1 mm or less in Breslow thickness ( Table 2 ). The median Breslow thickness of invasive melanomas in screened patients was significantly lower than that in unscreened patients (0.37 vs 0.65 mm; P < .001). The median age of patients diagnosed with melanoma was 64 years in the screened population and 62 years in the unscreened group (P =.54).
Key Points
Question Does population-based skin cancer screening result in increased detection of early-stage melanoma?
Findings Offering melanoma screening to patients 35 years or older presenting for a routine primary care visit in a large health care system resulted in higher rates of melanoma detection, particularly of thin, earlier-stage melanoma, among screened vs unscreened patients. This approach also resulted in a higher rate of screening than previous screening interventions among men and older patients, the groups at highest risk of melanoma.
Meaning Population-based screening for melanoma results in detection of thinner tumors and has the potential to reduce melanoma mortality.
Discussion
Through this initiative, 53 196 patients were screened for skin cancer in 1 year. Melanoma incidence in the screened population was more than double that in the unscreened population, and melanomas in screened patients were thinner than those in unscreened patients, which is a clinically significant finding. Breslow depth is the strongest indicator of melanoma mortality.
Cancer screening programs may be associated with increased incidence owing to overdiagnosis, particularly of potentially indolent cancers. While it is true that predominantly thin melanomas were detected in the present program, more people actually die from melanomas thinner than 1 mm than from those thicker than 4 mm. The thinner lesions have a lower case-based mortality rate, but their incidence is much greater in the population, hence the potential importance of their diagnosis. 8 The differences we observed in melanoma thickness and incidence are encouraging. In addition, our group Abbreviation: RR, relative risk.
a Per 100 000 persons.
b Relative risk for melanoma in the screened vs unscreened population.
c The P values are the P value of the screened vs unscreened effect for each corresponding melanoma category outcome. P values were not adjusted for multiple comparisons.
d Relative risk for melanoma in the screened vs unscreened population after adjustment for age, sex, race/ethnicity, and insurance status. Age was dichotomized as 57 years (median age) or younger and older than 57 years; race/ethnicity was categorized as white and other; insurance status was categorized as Medicare, commercial, and other.
e Two cases were excluded from this analysis due to missing information.
Research Brief Report A Large Skin Cancer Screening Quality Initiative previously showed that skin surgery and dermatology visits were not increased among patients seen by PCPs participating in this screening initiative, 9 suggesting that this initiative did not drive increased downstream health care costs. Our findings are observational rather than the results of a randomized trial, and thus there may be factors that influence which patients were screened and the quality of our data, given our "real world" setting and use of the EHR rather than standardized case report forms for data collection. Screenings may not have been counted if the physician did not indicate in the EHR that screening was performed. The PCPs were not required to complete INFORMED training, and clinicians were not compensated for screening above what was paid for the office visit in which the FBSE was performed. This initiative took place in a large, but not closed, health care system; thus, screenings performed and melanomas diagnosed outside the system could not be captured with certainty.
Conclusions
The ability to screen a high number of patients as part of a quality initiative in a large health care system with both academic and community-based physicians and to use the EHR to encourage screening and track outcomes are strengths of the intervention and potentially can serve as a blueprint for other similar, large-scale interventions. Future studies will be needed to definitively quantify the impact of this approach on melanoma thickness, mortality, and health care costs and to determine which patients benefit most from screening. However, we show in the current intervention that screening with FBSE can be performed on a large scale without additional physician compensation and may increase detection of melanoma at its most curable stages.
